Pilot Study on Cerebrospinal Fluid and Blood Plasma Liquid Biopsy in Patients with Metastatic Solid Tumors and Primary Central Nervous System Tumors

What this Trial Is About

Researchers are studying the use of cerebrospinal fluid CSF and blood plasma liquid biopsy to better understand metastatic solid tumors and primary central nervous system CNS tumors. This pilot study looks at how CSF-based liquid biopsy can provide information about CNS involvement in patients with solid tumors, including those with leptomeningeal disease, brain metastases, no CNS metastases, and primary CNS tumors. The goal is to evaluate the feasibility and usefulness of CSF analysis compared to plasma-based liquid biopsy across different patient groups. Participants will have a one-time collection of CSF through lumbar puncture or an Ommaya reservoir, along with a blood sample for plasma-based liquid biopsy. The study includes four cohorts defined by CNS disease status. The project aims to assess the presence of CSF biomarkers like cytology and circulating tumor DNA ctDNA, compare ctDNA results between CSF and plasma, and explore proteomic analysis of CSF samples especially in patients who test positive for biomarkers. Participants will undergo this single collection procedure, and data will be gathered on CSF and plasma biomarkers within 2 to 4 weeks from enrollment. Researchers will analyze the presence of CSF biomarkers in each cohort and compare them to plasma results. This study will help understand the potential role of CSF liquid biopsy in detecting CNS disease involvement and may inform future diagnostic approaches. The total involvement is brief, centered around this one-time sample collection and subsequent laboratory assessments.

Exploring the Feasibility of Cerebrospinal Fluid (CSF) and Blood Plasma Liquid Biopsy in Patients With Metastatic Solid Tumours and Primary Central Nervous System (CNS) Tumours: A Pilot Study